Aim/Introduction: A patient death shortly after a radionuclide therapy is rare. Nevertheless, this situation can be complicated to manage byhealthcare professionals, undertakers, and crematorium staff as there are few radiation protection guidelines, and especially for the newtherapeutic radionuclides. That is why, at the request of the French nuclear safety authority (ASN), the French Institute for radiationprotection and nuclear safety (IRSN) performed a study (1) about occupational radiation protection issues in the case where a patient diesshortly after radionuclide therapy with new radiopharmaceuticals. The objectives of this piece of work were to perform a synthesis of therecommendations about death and cremation of nuclear medicine patients, and to assess the doses which could be received by undertakers(performing transport and embalming of the body) and crematorium staff. Materials and Methods: IRSN reviewed Europeanrecommendations about death and cremation. These European data were completed with some recommendations from countries outsideEurope (USA, Canada) and data from international organisations (i.e. International Commission on Radiological Protection, and InternationalAtomic Energy Agency). For 4 most promising new therapeutic radionuclides identified in a previous IRSN study (2) - Lutetium-177, Radium-223, Holmium-166, and Actinium-225 - the doses which could be received by undertakers and crematorium staff were assessed usingrealistic scenarios and conservative hypotheses. For instance, for transport and embalming, the times of presence near the body, namely at50 cm, were 1 and 2 hours, respectively. Results: For Radium-223 and Actinium-225, the immediate transport and embalming of the body ispossible as the assessed doses for undertakers are negligible. For Lutetium-177 and Holmium-166, a few days period after the death isnecessary before the transport and the embalming to comply with regulatory dose constraints, without exceeding the French legal timeframe for funeral operations.For cremation, the assessed doses are usually under 0.3 mSv per cremation (excepted for Actinium-225). Conclusion: Considering the assessed occupational doses, practical radiation protection proposals were established in case of a patientdeath shortly after radionuclide therapy, which may be useful for radiation protection authorities, undertakers, and crematorium staff. References: (1) French Institute for Radiation Protection and Nuclear Safety (IRSN), Avis 2023-00004, January 2023,https://www.irsn.fr/sites/default/files/2023-02/Avis-IRSN-2023-00004.pdf (2) French Institute for Radiation Protection and Nuclear Safety (IRSN), Nouveaux radionucléides en médecine nucléaire - Première partie : étude bibliographique des nouveaux radionucléides et perspectives d’utilisation clinique en France - Rapport IRSN 2021-00083, February2021, https://www.irsn.fr/FR/expertise/rapports_expertise/Documents/radioprotection/IRSN_Rapport-2021-00083-nouveaux-radionucleides-medecine.pdf